HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite
 Help
Order: Signal: Tickers:
Filters
Overview Valuation Financial Ownership Performance Technical Custom Charts Tickers Basic TA News Snapshot Maps Stats
Total: 123 #1 Type: candle | line | technical    Timeframe: intraday | daily | weekly | monthly    Auto Refresh: 3min | off
TickerPIXY [NASD]
CompanyShiftPixy, Inc.
CountryUSA
IndustryStaffing & Employment Services
Market Cap8.74MEPS (ttm)-133.90
P/E-EPS this Y83.70%
Forward P/E-EPS next Y-
PEG-EPS past 5Y22.10%
P/S0.23EPS next 5Y-
P/B0.05EPS Q/Q-47.20%
Dividend-Sales Q/Q1.10%
Insider Own40.50%Inst Own3.30%
Insider Trans0.00%Inst Trans-99.08%
Short Float0.05%Earnings-
Analyst Recom-Target Price-
Avg Volume73.08K52W Range11.06 - 203.00
Sep-08-22 10:07AMShiftPixy stock soars on record volume, after plan to spin off ShiftPixy Labs business MarketWatch
Sep-08-22 08:00AMShiftPixy Announces Plans to Spin-off ShiftPixy Labs and Dividend its Digital Securities to Shareholders Business Wire
Sep-07-22 08:00AMShiftPixy Announces Application for Dual Listing on Upstream Business Wire
Aug-31-22 12:44PMShiftPixy, Inc. Announces Reverse Stock Split Effective Date Business Wire
May-24-22 04:15PMShiftPixy, Inc. Announces Management Changes Business Wire
May-13-22 07:30AMShiftPixy, Inc. Announces Special Distribution of Shares of Industrial Human Capital, Inc. Business Wire
Mar-18-22 05:00PMShiftPixy, Inc. Announces Revised SPAC Sponsorship Business Wire
Feb-08-22 03:59PMShiftPixy Is Giving Itself Many Ways to Win by Diversifying Its Business InvestorPlace
Feb-01-22 07:00AMCEO Presenting on the Emerging Growth Conference on February 2 Register Now GlobeNewswire
Jan-24-22 02:16PMShort Squeeze Stocks: PIXY, MBOT and 3 Others Experts Think Are Ready to Pop InvestorPlace
TickerPPBT [NASD]
CompanyPurple Biotech Ltd.
CountryIsrael
IndustryBiotechnology
Market Cap40.97MEPS (ttm)-0.77
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-
P/S-EPS next 5Y-
P/B0.58EPS Q/Q-
Dividend-Sales Q/Q-
Insider Own-Inst Own11.23%
Insider Trans-Inst Trans-
Short Float4.67%EarningsAug 04/b
Analyst Recom-Target Price-
Avg Volume42.62K52W Range2.10 - 5.18
Aug-04-22 07:30AMPurple Biotech Reports Second Quarter 2022 Financial Results GlobeNewswire
Jul-14-22 07:30AMPurple Biotech Announces Executive Leadership Changes GlobeNewswire
May-27-22 07:15AMPurple Biotech Presents Phase 1 Interim Monotherapy Data for NT219 at ASCO 2022, Demonstrating Encouraging Safety & Efficacy Profile GlobeNewswire
May-18-22 08:18AMPurple Biotech Announces the Initiation of Phase 2 Study for CM24 in 2L PDAC Patients GlobeNewswire
May-12-22 08:13AMPurple Biotech Reports First Quarter 2022 Financial Results GlobeNewswire
Apr-11-22 07:37AMPurple Biotech Presents Positive Interim Phase 1b Study Results for CM24 at the American Association of Cancer Research 2022 Annual Meeting GlobeNewswire
Feb-24-22 12:12AMCould The Solid State plc (LON:SOLI) Ownership Structure Tell Us Something Useful? Simply Wall St.
Feb-09-22 07:00AMPurple Biotech Reports Second Half and Full-Year 2021 Financial Results GlobeNewswire
Feb-04-22 07:35AMPurple Biotech Issues Letter to Shareholders GlobeNewswire
Jan-06-22 07:30AMPurple Biotech Appoints Life Sciences Industry Investor Ori Hershkovitz to its Board of Directors GlobeNewswire
TickerNEXI [NASD]
CompanyNexImmune, Inc.
CountryUSA
IndustryBiotechnology
Market Cap30.18MEPS (ttm)-2.68
P/E-EPS this Y-65.20%
Forward P/E-EPS next Y39.10%
PEG-EPS past 5Y-
P/S-EPS next 5Y-
P/B0.52EPS Q/Q-28.70%
Dividend-Sales Q/Q-
Insider Own11.60%Inst Own34.60%
Insider Trans27.58%Inst Trans-12.94%
Short Float2.95%Earnings-
Analyst Recom1.70Target Price3.50
Avg Volume1.16M52W Range1.01 - 18.78
Sep-08-22 07:00AMSelexis and NexImmune Sign Service Agreement to Advance Multiple Immunotherapies Targeting Rare Cancers and Autoimmune Disorders Business Wire
Sep-03-22 08:19AMBullish insiders bet US$1.7m on NexImmune, Inc. (NASDAQ:NEXI) Simply Wall St.
Aug-15-22 04:05PMNexImmune Reports Second Quarter 2022 Financial Results and Highlights FDA Clearance of IND for NEXI-003 for the Treatment of HPV-Related Cancers GlobeNewswire
Jul-20-22 11:42AMBiotech Stock Roundup: APLS, NVAX Gain on Updates, INCYs Regulatory News & More Zacks
Jul-18-22 08:20AMCan NexImmune (NASDAQ:NEXI) Afford To Invest In Growth? Simply Wall St.
Jul-15-22 11:00AMNexImmune (NEXI) IND Gets Clearance for HPV-Related Cancer Drug Zacks
Jul-14-22 04:09PMNexImmune Announces IND Clearance by the US FDA for NEXI-003 for the Treatment of HPV-Related Cancers GlobeNewswire
Jun-10-22 12:00PMWhat Makes NexImmune, Inc. (NEXI) a New Buy Stock Zacks
May-12-22 04:01PMNexImmune Reports First Quarter 2022 Financial Results and Provides Business Updates GlobeNewswire
May-10-22 04:01PMNexImmune, Yale, and JDRF Enter into Research Partnership for Type 1 Diabetes GlobeNewswire
TickerRUBY [NASD]
CompanyRubius Therapeutics, Inc.
CountryUSA
IndustryBiotechnology
Market Cap63.64MEPS (ttm)-2.23
P/E-EPS this Y-7.40%
Forward P/E-EPS next Y6.40%
PEG-EPS past 5Y-
P/S-EPS next 5Y-
P/B0.82EPS Q/Q12.60%
Dividend-Sales Q/Q-
Insider Own5.20%Inst Own87.30%
Insider Trans0.64%Inst Trans-14.74%
Short Float4.17%EarningsAug 09/b
Analyst Recom2.20Target Price6.80
Avg Volume1.17M52W Range0.65 - 21.67
Aug-11-22 12:00PMRubius Therapeutics, Inc. (RUBY) Upgraded to Buy: What Does It Mean for the Stock? Zacks
Aug-09-22 08:00AMRubius Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update GlobeNewswire
Jul-26-22 08:00AMRubius Therapeutics to Announce Second Quarter 2022 Financial Results GlobeNewswire
Jul-19-22 07:00AMHotSpot Therapeutics Appoints Jose Carmona to Board of Directors PR Newswire
Jul-14-22 08:00AMRubius Therapeutics Appoints Susanne Schaffert, Ph.D., to its Board of Directors GlobeNewswire
Jun-22-22 08:00AMRubius Therapeutics Presents Updated Data from its Type 1 Diabetes Preclinical Program at the Federation of Clinical Immunology Societies (FOCIS) 2022 Annual Meeting GlobeNewswire
Jun-01-22 08:00AMRubius Therapeutics to Present at the Jefferies Global Healthcare Conference GlobeNewswire
May-26-22 05:00PMRubius Therapeutics to Present Trials in Progress Poster for the Phase 1/2 Clinical Trial of RTX-224 in Select Advanced Solid Tumors at the 2022 American Society of Clinical Oncology Annual Meeting GlobeNewswire
May-24-22 08:00AMRubius Therapeutics Appoints Noubar Afeyan as Chairman of its Board of Directors GlobeNewswire
May-13-22 01:44PMStock rebound uncertain for U.S. biotechs as risks multiply for investors American City Business Journals
TickerIMPX [NYSE]
CompanyAEA-Bridges Impact Corp.
CountryCayman Islands
IndustryShell Companies
Market Cap500.50MEPS (ttm)-0.11
P/E-EPS this Y124.00%
Forward P/E-EPS next Y-
PEG-EPS past 5Y-
P/S-EPS next 5Y-
P/B-EPS Q/Q-53.40%
Dividend-Sales Q/Q-
Insider Own6.25%Inst Own87.40%
Insider Trans0.00%Inst Trans-0.21%
Short Float0.14%Earnings-
Analyst Recom-Target Price-
Avg Volume80.04K52W Range9.73 - 10.32
Jul-28-22 07:00AMHarley-Davidson Delivers Second Quarter Financial Results PR Newswire
May-20-22 10:11AMMichael Burry is Shorting Apple (AAPL) and Selling These 5 Stocks in 2022 Insider Monkey
Apr-28-22 04:47PMHarley-Davidson Is Cruising in Neutral GuruFocus.com
Apr-27-22 07:00AMHarley-Davidson Delivers First Quarter Financial Results PR Newswire
Mar-21-22 09:08AMMichael Burrys Warning On Inflation and His Top 6 Stock Picks Insider Monkey
Feb-17-22 05:26AM6 Best Stocks to Buy According to Michael Burry Insider Monkey
Feb-08-22 06:50AMHarley-Davidson delivers strong fourth quarter financial results and successfully completes the first year of The Hardwire Five-year Strategic Plan PR Newswire
Dec-21-21 02:51PMMoore Kuehn Encourages IMPX, CCMP, FOUN, and JUPW Investors to Contact Law Firm PR Newswire
Dec-18-21 10:26AMSHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of AEA-Bridges Impact Corp. (NYSE - IMPX) ACCESSWIRE
Dec-16-21 04:38PMInvestor Alert: The M&A Class Action Firm Announces an Investigation of the Merger PR Newswire
TickerIMRA [NASD]
CompanyIMARA Inc.
CountryUSA
IndustryBiotechnology
Market Cap51.03MEPS (ttm)-2.08
P/E-EPS this Y32.90%
Forward P/E-EPS next Y68.50%
PEG-EPS past 5Y-
P/S-EPS next 5Y-
P/B0.86EPS Q/Q41.40%
Dividend-Sales Q/Q-
Insider Own2.10%Inst Own59.50%
Insider Trans4.55%Inst Trans-2.82%
Short Float0.88%EarningsAug 05/b
Analyst Recom3.00Target Price1.20
Avg Volume1.69M52W Range0.97 - 4.62
Sep-07-22 03:35PMImara divests from sickle cell treatment research Yahoo Finance Video
Sep-07-22 09:05AMAfter Disappointing Data, Imara Offloads It Sickle Cell Candidate, Shares Surge Benzinga
Aug-25-22 06:15AMA IMARA Inc. (NASDAQ:IMRA) insider increased their holdings by 195% last year Simply Wall St.
Jul-15-22 06:55AMWill IMARA (NASDAQ:IMRA) Spend Its Cash Wisely? Simply Wall St.
May-19-22 12:00PMWhat Makes IMARA Inc. (IMRA) a New Buy Stock Zacks
Apr-05-22 06:45AMImara Announces Results of Interim Analyses of Tovinontrine (IMR-687) Phase 2b Clinical Trials in Sickle Cell Disease and Beta-Thalassemia GlobeNewswire
Mar-15-22 07:00AMImara Reports Full Year 2021 Financial Results and Business Highlights GlobeNewswire
Mar-09-22 06:24AM7 Biotech Stocks With Key Catalysts in March InvestorPlace
Mar-08-22 07:00AMImara to Webcast Conference Call of Full Year 2021 Financial Results and Business Highlights GlobeNewswire
Feb-19-22 07:10AMDavid Mott Is The Independent Chairman of IMARA Inc. (NASDAQ:IMRA) And They Just Picked Up 144% More Shares Simply Wall St.
TickerPONO [NASD]
CompanyPono Capital Corp.
CountryUSA
IndustryShell Companies
Market Cap151.34MEPS (ttm)0.60
P/E16.80EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-
P/S-EPS next 5Y-
P/B1.34EPS Q/Q-
Dividend-Sales Q/Q-
Insider Own0.83%Inst Own94.50%
Insider Trans0.00%Inst Trans2.21%
Short Float0.01%Earnings-
Analyst Recom-Target Price-
Avg Volume40.18K52W Range5.36 - 10.19
Sep-07-22 04:15PMAERWINS Technologies Inc., an air mobility platform company, announces signing of a definitive agreement for going public via a business combination with Pono Capital Corp., a NASDAQ listed company, to become a public company. GlobeNewswire
Aug-10-22 05:25PMPono Capital Corp Confirms Funding to Extend Period to Consummate Initial Business Combination GlobeNewswire
Aug-10-22 05:25PMPono Capital Corp Announces Termination of Merger Agreement with Benuvia, Inc. GlobeNewswire
Mar-18-22 06:00AMBenuvia, a Leading Drug Developer Focused on Pharmaceutical Cannabinoids, with the FDA Approved Drug SYNDROS®, Signs Definitive Agreement to Become a Publicly Traded Company through a Business Combination with Pono Capital Corp GlobeNewswire
TickerINM [NASD]
CompanyInMed Pharmaceuticals Inc.
CountryCanada
IndustryBiotechnology
Market Cap124.54MEPS (ttm)-1.37
P/E-EPS this Y34.20%
Forward P/E-EPS next Y51.00%
PEG-EPS past 5Y-
P/S216.71EPS next 5Y-
P/B5.97EPS Q/Q-
Dividend-Sales Q/Q-
Insider Own0.78%Inst Own9.05%
Insider Trans25.83%Inst Trans-
Short Float-Earnings-
Analyst Recom3.00Target Price3.40
Avg Volume35.45K52W Range5.82 - 59.25
Aug-23-22 05:00PMInMed Announces Share Consolidation to Meet Nasdaq Listing Criteria GlobeNewswire
Aug-09-22 07:30AMInMed Announces Changes to its Board of Directors GlobeNewswire
Jul-25-22 07:30AMInMed Announces Update on Phase 2 Clinical Trial Investigating INM-755 Cannabinol Cream for Epidermolysis Bullosa GlobeNewswire
Jul-18-22 07:30AMInMed Announces Appointment of Chief Operating Officer GlobeNewswire
Jul-12-22 11:33PMInMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Compliance GlobeNewswire
Jun-14-22 07:30AMInMed Announces Publication of Peer-Reviewed Study Highlighting Potential Role of Rare Cannabinoids THCV, CBC and others on Skin Conditions GlobeNewswire
Jun-09-22 07:30AMInMed Launches THCV, Expanding its Portfolio of Rare Cannabinoids for the Health and Wellness Sector GlobeNewswire
Jun-06-22 06:49PMInMed Pharmaceuticals Announces Closing of $5 Million Registered Direct and Private Placement Offerings Priced At-The-Market Under Nasdaq Rules GlobeNewswire
Jun-02-22 08:00AMInMed Pharmaceuticals Announces $5 Million Registered Direct and Private Placement Offerings Priced At-The-Market Under Nasdaq Rules GlobeNewswire
May-13-22 08:45AMInMed Pharmaceuticals Inc. (INM) Reports Q3 Loss, Misses Revenue Estimates Zacks
TickerDNL [NYSE]
CompanyWisdomTree Global ex-U.S. Quality Dividend Growth Fund
CountryUSA
IndustryExchange Traded Fund
Market Cap-EPS (ttm)-
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-
P/S-EPS next 5Y-
P/B-EPS Q/Q-
Dividend4.16%Sales Q/Q-
Insider Own-Inst Own-
Insider Trans-Inst Trans-
Short Float-Earnings-
Analyst Recom-Target Price-
Avg Volume90.61K52W Range29.80 - 43.77
May-27-21 08:30AMWisdomTree Announces ETF Share Splits GlobeNewswire
Aug-12-20 01:30PMBest Dividend ETFs for Q4 2020 Investopedia
May-08-20 09:52AMKiplinger ETF 20: Our Strategic Funds Shine Kiplinger
Dec-17-19 03:02PMTop Foreign ETFs of 2019 Zacks
Nov-20-19 11:00AMForget Dividend Growth Slowdown With These ETFs Zacks
Apr-18-19 06:00PMThe 19 Best ETFs to Buy for a Prosperous 2019 Kiplinger
Aug-06-18 05:13PMMore Star Power for the Kiplinger ETF 20 Kiplinger
Jan-03-18 10:15AMWisdomTree Expands Offering on Schwab ETF OneSource GlobeNewswire
Aug-01-17 02:01AMTobacco Stock Woes Burns Investors in Low-Vol, Dividend Funds The Wall Street Journal
Aug-01-17 12:44AMTobacco Stock Woes Burns Investors in Low-Vol, Dividend Funds The Wall Street Journal
TickerATXI [NASD]
CompanyAvenue Therapeutics, Inc.
CountryUSA
IndustryBiotechnology
Market Cap5.04MEPS (ttm)-0.27
P/E-EPS this Y29.70%
Forward P/E-EPS next Y-
PEG-EPS past 5Y10.40%
P/S-EPS next 5Y-
P/B7.51EPS Q/Q51.90%
Dividend-Sales Q/Q-
Insider Own51.45%Inst Own3.10%
Insider Trans0.00%Inst Trans-34.73%
Short Float0.77%Earnings-
Analyst Recom3.00Target Price-
Avg Volume271.47K52W Range0.20 - 1.85
Mar-31-22 07:30AMAbeona Therapeutics Announces Strategy Update and 2021 Financial Results GlobeNewswire
Feb-16-22 08:20AMFDA's AdComm Says Avenue Therapeutics Submitted Insufficient Data On IV Tramadol Benzinga
Feb-15-22 10:00PMAvenue Therapeutics Announces Outcome of FDA Advisory Committee Meeting on IV Tramadol GlobeNewswire
Feb-15-22 07:05AMAvenue Therapeutics Stock Trading Halted Today GlobeNewswire
Dec-15-21 02:15PMAegis Capital Corp. Acted as Sole Bookrunner on a $2 Million Public Offering of Common Stock for Avenue Therapeutics (NASDAQ: ATXI) ACCESSWIRE
Dec-15-21 12:00PMAvenue Therapeutics Announces Closing of Public Offering of Common Stock GlobeNewswire
Dec-12-21 08:00PMAvenue Therapeutics Prices $2.0 Million Underwritten Public Offering of Common Stock GlobeNewswire
Nov-29-21 08:00AMAvenue Therapeutics Announces FDA Advisory Committee Meeting to Review IV Tramadol NDA Tentatively Scheduled for February 15, 2022 GlobeNewswire
Nov-17-21 09:30AMAvenue Therapeutics Announces Exercise and Closing of Underwriters Over-Allotment Option GlobeNewswire
Nov-12-21 10:40AMAegis Capital Corp. acted as Sole Bookrunner on a $2.6 Million Public Offering of Common Stock for Avenue Therapeutics (NASDAQ: ATXI) ACCESSWIRE
123456 ... 10 ... 13next
affiliate • advertise • contact • privacy • help
Do Not Sell My Data • Privacy Settings
Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2022 FINVIZ.com. All Rights Reserved.